3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Dermatologic
1
Conditions
Melanoma
5
Neoplasms
3
Glioma
3
Glioblastoma
3
Squamous Cell Carcinoma of Head and Neck
2
Gliosarcoma
2
Central Nervous System Neoplasms
2
Brain Neoplasms
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Head and Neck Neoplasms
1
Ependymoma
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
Cisplatin
131
Cetuximab
80
Radiotherapy
76
Docetaxel
59
Carboplatin
46
pembrolizumab
45
Paclitaxel
44
Fluorouracil
42
Radiotherapy, Intensity-Modulated
35
Drug Therapy
17
Radiation
14
Nivolumab
14
Gefitinib
14
Gemcitabine
13
Surgical Procedures, Operative
12
Oxaliplatin
11
Erlotinib Hydrochloride
11
130-nm albumin-bound paclitaxel
11
Pemetrexed
10
Celecoxib
10
Capecitabine
10
Bevacizumab
10
tislelizumab
9
Filgrastim
9
Amifostine
9
Albumin-Bound Paclitaxel
9
durvalumab
7
atezolizumab
7
Chemoradiotherapy
7
toripalimab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Head and Neck Neoplasms
×
poly ICLC
×
Clear all
NCT02423863
2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2
Completed
26 enrolled